Related Experiment Videos
Interleukin-12, interleukin-23, and psoriasis: current prospects
Dorothea C Torti1, Steven R Feldman
1Dartmouth Medical School, Lebanon, New Hampshire, USA.
Journal of the American Academy of Dermatology
|August 21, 2007
Summary
New therapies targeting interleukin-12 (IL-12) and IL-23 show promise for treating psoriasis. While generally well-tolerated in early trials, further research is needed to assess long-term safety and efficacy.
Area of Science:
- Immunodermatology
- Cytokine Biology
- Therapeutic Development
Background:
- Psoriasis pathogenesis involves T cells and inflammatory cytokines, notably IL-12 and IL-23.
- IL-12 and IL-23 share a common subunit (p40), making them targets for combined therapy.
- Genetic deficiencies in IL-12 suggest potential risks associated with anti-IL-12/IL-23 therapies.
Purpose of the Study:
- To review existing literature on IL-12 and IL-23 in psoriasis.
- To understand the basis for anti-IL-12/IL-23 therapy in treating psoriasis.
- To evaluate the safety and efficacy of novel therapeutic strategies.
Main Methods:
- Literature review using PubMed for English-language articles.
- Analysis of studies on IL-12, IL-23, and their role in psoriasis.
- Examination of preclinical (transgenic/knockout mice) and clinical trial data.
Main Results:
- IL-12 p40 antibody demonstrated good tolerability and psoriasis improvement in Phase I trials.
- Phase II trials confirmed dose-dependent efficacy and significant patient improvement.
- Preclinical models indicated potential adverse events related to IL-12 deficiency.
Conclusions:
- Anti-IL-12/IL-23 therapies represent a promising treatment avenue for psoriasis.
- Early clinical trials suggest favorable safety and efficacy profiles.
- Extended trials are necessary to fully evaluate clinical utility and potential adverse events, including infections.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:21EPS and iPS Cells in Disease Research
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...